Lima, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Lima, Peru, December 12, 2025 – Credicorp Ltd. (“Credicorp”) (NYSE: BAP | BVL: BAP) announces to its shareholders and the market the schedule for issuing the 2026 quarterly earnings releases and hosting the corresponding conference calls: 1Q26Earnings Release – Thursday, May 14, 2026Conference Call – Friday, May 15, 2026 2Q26Earnings Release – Thursday, August 13, 2026Conference Call – Friday, August 14, 2026 3Q26Earnings Release – Monday, November 9, 2026Conference C ...

TULSA, Okla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Vital Energy, Inc. (NYSE: VTLE) ("Vital Energy" or the "Company") today announced that, at a special meeting of Vital Energy stockholders held today, the stockholders of the Company approved the previously announced merger (the "Merger") between Vital Energy and Crescent Energy Company ("Crescent"). Vital Energy will file the final vote results for its special meeting on a Form 8-K with the U.S. Securities and Exchange Commission (the "SEC"). The Merger is ant ...

TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2025 and provided an update on its business. During the year, the company initiated manufacturing activities for a Phase 2 study of Edesa’s dermatology drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in patients with moderat ...

Final Short Form Prospectus Accessible on SEDAR+Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- FireFly Metals Ltd (ASX: FFM, TSX: FFM) (FireFly or Company) is pleased to announce that, in connection with its previously announced bought deal offering, it has filed a final short form prospectus dated 12 December 2025 (Final Prospectus) to qualify the distribution of 19,230,770 ordinary shares of the Company (Offered Shares) at ...

Management to host conference call on Monday, December 15, 2025, at 4:30 PM ET PINE MOUNTAIN, Georgia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Parks! America, Inc. (OTCQX: PRKA), today announced its financial results for the fourth fiscal quarter and fiscal year ended September 28, 2025. The summary information in this press release should not be used as the sole basis for making investment decisions. We encourage shareholders to read our complete Form 10-K, which has been posted on the Investor Info section of t ...

WESTCHESTER, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions, announced today that its board of directors has declared a quarterly dividend of $0.82 per share on the Company’s common stock. The quarterly dividend will be payable on Jan. 20, 2026, to stockholders of record at the close of business on Jan. 2, 2026. For additional information about Ingredion Incorporated, including investor relations, financial updates, and upcoming ...

CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on December 11, 2025 (the “Grant Date”), the Company’s Board of Directors granted non-qualified stock options to purchase an a ...

Kfar Saba, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced the successful demonstration of its advanced DefendAir counter-UAS (C-UAS) system at a high-profile event organized by the International Defense Cooperation Directorate (SIBAT) at the Israel Ministry of Defense’s (IMOD) demonstration fa ...

LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof), Series F warrants to purchase up to 10,666,667 shares of com ...

Core Viewpoint - Anavex Life Sciences Corp. is facing a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding its marketing authorization application for blarcamesine to treat early Alzheimer's disease, and the company plans to request a re-examination of this decision [2][3] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome [1][5] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [5] Alzheimer's Disease Context - Alzheimer's disease accounts for 60-80% of all dementia cases globally, representing a significant unmet need for new treatment options to slow disease progression and alleviate the burden on patients and society [4]